Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25840367 | 1.00 | HRH3 (0.52) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL22861342 | 1.00 | HRH3 (0.52) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL23815629 | 0.90 | HRH3 (0.42) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL15101577 | 0.84 | HRH3 (0.65) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL20729452 | 0.83 | HTR1A (0.54) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL22281966 | 0.83 | HTR1A (0.54) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL20729427 | 0.83 | HTR1A (0.54) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| SCHEMBL12449633 | 0.81 | HRH3 (0.56) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL13052 | 0.81 | HRH3 (0.56) | HRH3MAOBHRH2HRH1KDM4E | |
| SCHEMBL12449644 | 0.81 | HRH3 (0.56) | HRH3MAOBHRH2HRH1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | HRH3 3363/4885MAOB 4449/4885HRH2 3574/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | HRH3 3604/4885MAOB 4700/4885HRH2 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.